Denali Therapeutics stock (US24823R1077): FDA priority review for Hunter syndrome drug

Denali Therapeutics Inc. (Nasdaq: DNLI) announced on July 7, 2025, that the U.S. Food and Drug Administration accepted and granted priority review to its Biologics License Application for tividenofusp alfa, an investigational therapy for Hunter syndrome (MPS II), according to StockTitan as of July 7, 2025. The PDUFA target action date is January 5, 2026. Shares declined 3.00% on the news publication day.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Denali Therapeutics: core business model

Denali Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to defeat neurodegenerative and lysosomal storage diseases using its proprietary TransportVehicle platform, which enables therapeutics to cross the blood-brain barrier, according to Morningstar. The platform underpins candidates like tividenofusp alfa (DNL310), designed for Hunter syndrome by delivering the IDS enzyme to the brain and periphery.

Key programs target Parkinson's disease with LRRK2 inhibitors such as DNL201 and DNL151, and other assets like DNL747, ATV, and ETV. Denali's approach differentiates it in biotech by addressing central nervous system challenges in rare diseases.

Main revenue and product drivers for Denali Therapeutics

Tividenofusp alfa's BLA, supported by Phase 1/2 data from 47 participants, seeks accelerated approval for Hunter syndrome, a rare genetic disorder affecting neurological and physical functions, per the July 7, 2025 press release. The ongoing Phase 2/3 COMPASS study supports potential global approvals. Denali has received Fast Track, Breakthrough Therapy, and Priority Medicines designations for this asset.

Early launch signals for Avlayah, another Hunter syndrome therapy, show enthusiasm with first commercial patients treated in April 2026, according to Oppenheimer via Marketscreener. HC Wainwright expressed optimism on DNLI earnings potential as of May 12, 2026, per MarketBeat.

Why Denali Therapeutics matters for US investors

Listed on Nasdaq, Denali Therapeutics offers US investors exposure to innovative biotech addressing unmet needs in neurodegenerative diseases, a sector with significant US market potential given high prevalence and R&D investment. FDA priority review highlights regulatory momentum relevant to American markets.

Conclusion

Denali Therapeutics continues advancing its TransportVehicle platform with FDA priority review for tividenofusp alfa in Hunter syndrome, alongside positive Avlayah launch signals and analyst optimism. The PDUFA date in January 2026 represents a key milestone. Investors track biotech progress amid clinical and regulatory developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.